NCT04940364View on ClinicalTrials.gov

A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Healthy

Interventions

DRUG

Pozelimab

Administered intravenous (IV) or subcutaneous (SC) per protocol

DRUG

Cemdisiran

Administered SC per protocol

Trial Locations (1)

SE1 1YR

Regeneron Research Site, London

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04940364 - A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers | Biotech Hunter | Biotech Hunter